Skip to main content
ImmunityBio, Inc. logo

ImmunityBio, Inc. — Investor Relations & Filings

Ticker · IBRX ISIN · US45256X1037 LEI · 529900J9XLBR4HFL4B83 US Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2026-06-10 Declaration of Voting R…
Country US United States of America
Listing US IBRX

About ImmunityBio, Inc.

https://immunitybio.com/

ImmunityBio, Inc. is a commercial-stage biotechnology company developing next-generation immunotherapies and vaccines designed to strengthen a patient's own immune system. The company's approach focuses on orchestrating both the innate (natural killer cells) and adaptive (T cells) immune systems to combat cancer and infectious diseases. Its key platforms include the IL-15 superagonist Anktiva® (N-803), engineered natural killer (NK) cell therapies, and adenovirus-vectored vaccines. These therapies are being investigated and applied across a range of difficult-to-treat cancers, such as bladder, lung, and pancreatic cancers, as well as infectious diseases like HIV. The company's goal is to create durable, complete responses by treating the host's immune system rather than just the disease.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K “Current Report” filed under Item 5.07 (“Submission of Matters to a Vote of Security Holders”). It provides the vote tallies for director elections and the ratification of the independent auditor at the company’s 2026 Annual Meeting of Stockholders. This constitutes an official report of shareholder voting results. Accordingly, it maps directly to the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-06-10 English
8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, disclosing the entry into a material definitive agreement and furnishing exhibits (press release). It does not present financial statements itself, nor is it a standalone earnings release, annual report, or management discussion. It is a regulatory filing for a material contract event, making it a general regulatory announcement (RNS).
2026-05-18 English
10-Q - ImmunityBio, Inc. (0001326110) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Earnings Release Classification · 85% confidence The document is a Form 8-K reporting Item 2.02 “Results of Operations and Financial Condition,” stating that the company issued a press release announcing its financial results for the quarter ended March 31, 2026. This is the initial announcement of quarterly financial results (key highlights) rather than a full interim report or just a report publication notice. Therefore it fits the Earnings Release category. Q1 2026
2026-05-07 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings Classification · 95% confidence The document is a press release announcing preliminary financial results for Q1 2026, including net product revenue and cash position, with forward-looking statements and operational highlights. It references the upcoming filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, indicating that the detailed financial report is forthcoming. The document does not contain comprehensive financial statements or detailed financial analysis itself, but rather summarizes preliminary results and business updates. It is not a full quarterly report (IR), nor an earnings release (ER) since it provides more detailed operational context and forward-looking commentary. Given the nature of the document as a preliminary financial and operational update press release, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and preliminary financial disclosures that do not constitute full reports.
2026-04-09 English
8-K - ImmunityBio, Inc. (0001326110) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 6, 2026. It announces the submission of a comprehensive response to a Warning Letter from the FDA and includes a press release as an exhibit. The document is short (3,719 characters) and primarily serves as a regulatory announcement of an event and related press release, not a full financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2026-04-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.